JD Health International Inc. (HKG:6618)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 133.83B -32.0% |
| Revenue (ttm) | 91.25B +21.4% |
| Net Income | 7.18B +31.7% |
| EPS | 2.24 +31.0% |
| Shares Out | 3.19B |
| PE Ratio | 18.74 |
| Forward PE | 15.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,189,609 |
| Open | 42.44 |
| Previous Close | 42.84 |
| Day's Range | 41.82 - 42.78 |
| 52-Week Range | 31.84 - 71.70 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 68.66 (+63.63%) |
| Est. Earnings | Nov 13, 2026 |
About JD Health International
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People’s Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical in... [Read more]
Financial Performance
In 2025, JD Health International's revenue was 73.44 billion, an increase of 26.28% compared to the previous year's 58.16 billion. Earnings were 5.38 billion, an increase of 29.16%.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for 6618 stock is "Strong Buy." The 12-month stock price target is $68.66, which is an increase of 63.63% from the latest price.
News
JD Health International Earnings Call Transcript: H1 2026
H1 revenue reached CNY 40.9bn, with product revenue up 15.6% YoY and non-IFRS operating income up 40.3%. Margin gains continued for a ninth quarter; H2 growth is expected to exceed the industry, while supplements face headwinds.
JD Health International Earnings release: H1 2026
JD Health International released its H1 2026 earnings on August 13, 2026, summarizing the period's financial results.
JD Health International Quarterly report: H1 2026
JD Health International has published its H1 2026 quarterly earnings report on August 13, 2026.
JD Health International Earnings Call Transcript: H2 2025
Revenue grew 26.3% year-over-year to RMB 73.4 billion, with non-IFRS profit up 36.3% and gross margin at 24.8%. Strategic partnerships, AI-driven services, and expanded product offerings fueled growth, while the company sees significant market potential ahead.
JD Health International Earnings release: H2 2025
JD Health International released its H2 2025 earnings on March 5, 2026, summarizing the period's financial results.
JD Health International Annual report: H2 2025
JD Health International has published its H2 2025 annual report on March 5, 2026.
